VEGF has emerged as a critical mediator of angiogenesis, required for invasive tumor growth and metastasis and, therefore, targeted antibodies against VEGF and its receptors have been introduced as potential antitumor therapy [17]–[19]. The gene discussed is VEGFA; the disease is neoplasm.